RAD51 and cancer: Our findings demonstrate that RAD51 is consistently overexpressed across pan‐cancer analyses and exhibits particularly pronounced upregulation in OSCC, where it shows high diagnostic power (AUC = 0.956 and 95% CI: 0.934–0.977).